Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: A retrospective analysis based on 229,042 patients with type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Wilke, Thomas ^a   Mueller, Sabrina ^a   Groth, Antje ^a   Fuchs, Andreas ^b   Seitz, Lisa ^c   Kienhöfer, Joachim ^c   Maywald, Ulf ^b   Lundershausen, Rainer ^d   Wehling, Martin ^e  

^a Hochschule Wismar   (Germany)

^b AOK Plus   (Germany)

^c Novo Nordisk Pharma GmbH   (Germany)

^d Diabetes Centre Erfurt Bad Berka   (Germany)

^e MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Diabetes related events; Macrovascular event risk; Mortality risk of type 2 diabetes mellitus patients, HbA1C; Type 2 diabetes mellitus

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ACCOMMODATION DISORDER; ACUTE HEART INFARCTION; AGE; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BODY MASS; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETES COMPLICATION SEVERITY INDEX; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY ASSESSMENT; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG USE; EVENT FREE SURVIVAL; FEMALE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; MIDDLE AGED; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84924288618     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0179-2     Document Type: Article

References (42)

1. Allen J, Bergmann E, Böhmer M, Busch M, Dölle R, Ellert U, et al. Daten und Fakten: Ergebnisse der Studie "Gesundheit in Deutschland aktuell 2009". Robert Koch-Institut: Beiträge zur Gesundheitsberichterstattung des Bundes; 2011. p. 73-5.
2. Liebl A, Neiß A, Spannheimer A, Reitberger U, Wagner T, Görtz A. Kosten der Typ-2 Diabetes in Deutschland. Ergebnisse der CODE-2-Studie. Dtsch Med Wschr. 2001;126:585-9.
3. Norgaard ML, Andersen SS, Schramm TK, Folke F, Jørgensen CH, Hansen ML, et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction-a nationwide study. Diabetologia. 2010;53(8):1612-9.
4. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalisation, and healthcare utilization. Am J Manag Care. 2008;14(1):15-23.
5. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721-6.
6. American Diabetes Association. Executive summary: standards of medical care in diabetes-2010. Diabetes Care. 2010;33(S1):S4-10.
7. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104(1):1-52.
8. Bundesärztekammer (BäK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes - Langfassung, 1. Auflage. Version 1 2013. [ http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_Therapie , accessed 19 December 2013]
9. Bonora E, Kiechl S, Mayr A, Zoppini G, Targher G, Bonadonna RC, et al. High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care. 2011;34(4):1038-40.
10. Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of haemoglobin A1c. J Intern Med. 2012;271(3):227-36.
11. Malkani S, Mordes JP. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med. 2011;124(5):395-401.
12. McBrien KA, Manns BJ, Chui B, Klarenbach SW, Rabi D, Ravani P, et al. Health care costs in people with diabetes and their association with glycemic control and kidney function. Diabetes Care. 2013;36(5):1172-80.
13. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34(6):1329-36.
14. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, et al. CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalisation for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008;168(15):1699-704.
15. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
16. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39.
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
18. Currie CJ, Peters JR, Tynan A, vans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481-9.
19. Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325-34.
20. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122(21):2142-51.
21. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068-74.
22. Umamahesh K, Vigneswari A, Surya Thejaswi G, Satyavani K, Viswanathan V. Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes - an 11-year follow up study. Indian Heart J. 2014;66(1):5-10.
23. Chae JW, Song CS, Kim H, Lee KB, Seo BS, Kim DI. Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron Clin Pract. 2011;117(4):c379-84.
24. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2014. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2013.
25. Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med. 2009;151(12):854-60.
26. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-66.
27. Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab. 2013;15(1):55-61.
28. Cronin O, Morris DR, Walker PJ, Golledge J. The association of obesity with cardiovascular events in patients with peripheral artery disease. Atherosclerosis. 2013;228:316-23.
29. Turner R, UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-13.
30. Volpe M, Tocci G. Redefining blood pressure targets in high-risk patients? Lessons from coronary endpoints in recent randomized trials. Am J Hypertens. 2011;24(10):1060-8.
31. Kowall B, Rathmann B. HbA1C for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform? Diabetes Metab Syndr Obes. 2013;6:477-91.
32. ORIGIN Trial Investigators, Mellbin LG, Rydén L, Riddle MC, Probstfield J, Rosenstock J, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34(40):3137-44.
33. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-28.
34. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342-56.
35. Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, et al. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2013;12:98.
36. Du YF, Ou HY, Beverly EA, Chiu CJ. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging. 2014;9:1963-80.
37. Jiao FF, Fung CS, Wong CK, Wan YF, Dai D, Kwok R, et al. Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care: a longitudinal comparative study. Cardiovasc Diabetol. 2014;13(1):127.
38. Novo S, Peritore A, Trovato RL, Guarneri FP, Di Lisi D, Muratori I, et al. Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up. Cardiovasc Diabetol. 2013;12(1):155.
39. Fabbian F, De Giorgi A, Monesi M, et al. All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used? Diab Vasc Dis Res. 2014. [Epub ahead of print]
40. Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Cederholm J. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register. Eur J Prev Cardiol. 2014;21(2):244-51.
41. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.
42. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96.